Patents by Inventor Babal K. Jha

Babal K. Jha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antitumor TET2 modulating compounds
    Patent number: 11865104
    Abstract: A method of treating cancer is described. The method includes administering a therapeutically effective amount of a TET2 activating compound or pharmaceutically acceptable salt thereof to a subject in need of treatment. The TET2 activating compounds are ?-ketoglutarate derivatives. A method of treating or preventing cancer in a subject that includes the step of analyzing a biological sample to determine if cells of the biological sample exhibit a TET2 mutation in addition to administering a TET2 activator is also described.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 9, 2024
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Jaroslaw Maciejewski, Babal K. Jha, James G. Phillips, Thomas Radivoyevitch, Yihong Guan, Anand D. Tiwari
  • BIOAVAILABLE PROTEIN DISULFIDE ISOMERASE INHIBITORS
    Publication number: 20230312552
    Abstract: Compounds according to formula (I) are described wherein R1 is an amino acid or a modified amino acid linked to the compound through a peptide bond, R2 is selected from CN, SO2CH3, NO2, CO2R3, CONHR3, NH2, NMe2 and CF3, and R3 is selected from H or lower alkyl, X is O or S, and Y is C—H or N, or a pharmaceutically acceptable salt thereof. The compounds can be used as protein disulfide isomerase inhibitors. The compounds can also be used in a method of treating or cancer in a subject.
    Type: Application
    Filed: August 27, 2021
    Publication date: October 5, 2023
    Inventors: Babal K. Jha, James G. Phillips, Frederic J. Reu, Metis Hasipek, Dale Grabowski, Jaroslaw P. Maciejewski
  • ANTITUMOR TET2 MODULATING COMPOUNDS
    Publication number: 20200306221
    Abstract: A method of treating cancer is described. The method includes administering a therapeutically effective amount of a TET2 activating compound or pharmaceutically acceptable salt thereof to a subject in need of treatment. The TET2 activating compounds are a-ketoglutarate derivatives. A method of treating or preventing cancer in a subject that includes the step of analyzing a biological sample to determine if cells of the biological sample exhibit a TET2 mutation in addition to administering a TET2 activator is also described.
    Type: Application
    Filed: November 29, 2018
    Publication date: October 1, 2020
    Inventors: Jaroslaw Maciejewski, Babal K. Jha, James G. Philips, Thomas Radivoyevitch, Yihong Guan, Anand D. Tiwari